US Nuclear Corp. Losses Widen Amid Revenue Drop, Raising Going Concern Doubts

TL;DR

**UCLE is bleeding cash and revenue, making it a highly speculative bet with significant risk of further dilution or failure.**

AI Summary

US NUCLEAR CORP. (UCLE) reported a significant increase in net loss for the three months ended March 31, 2025, reaching $560,232, a substantial rise from the $161,978 net loss in the prior-year period. This was primarily driven by a 75.2% surge in selling, general, and administrative expenses to $872,797 from $498,198. Revenue declined by 24.0% to $476,705 from $627,750, further exacerbating the operational loss, which widened to $523,880 from $144,429. The company's cash position decreased by 47.8% to $68,489 from $130,840 at December 31, 2024. Total current assets fell by 7.2% to $1,921,511, while total current liabilities decreased by 11.9% to $2,374,928. The accumulated deficit grew to $20,307,784, and the company explicitly stated a 'substantial doubt about its ability to continue as a going concern,' planning to seek additional capital through private placement offerings.

Why It Matters

UCLE's deepening losses and explicit 'going concern' warning signal significant distress for investors, indicating a high risk of further capital dilution or potential bankruptcy. The substantial decline in revenue and surge in operating expenses suggest a deteriorating competitive position in the radiation detection market, impacting future growth prospects and employee stability. For customers, this could raise concerns about long-term product support and innovation. The broader market may see this as a cautionary tale for micro-cap companies struggling with profitability and liquidity, especially those in niche technology sectors.

Risk Assessment

Risk Level: high — The company reported a net loss of $560,232 for the quarter and an accumulated deficit of $20,307,784 as of March 31, 2025, explicitly stating 'substantial doubt about its ability to continue as a going concern.' Cash decreased by 47.8% to $68,489, and sales dropped by 24.0% to $476,705, indicating severe operational and liquidity challenges.

Analyst Insight

Investors should avoid UCLE given the explicit going concern warning, significant net losses, and declining revenue. Existing shareholders should consider divesting, as further capital raises are likely to cause substantial dilution, and the company's long-term viability is highly questionable.

Financial Highlights

debt To Equity

N/A

revenue

$476,705

operating Margin

-110.1%

total Assets

$2,497,830

total Debt

$3,180,350

net Income

-$560,232

eps

-$0.01

gross Margin

73.2%

cash Position

$68,489

revenue Growth

-24.0%

Revenue Breakdown

Key Numbers

• $560,232 — Net Loss (Increased from $161,978 in prior year, indicating worsening profitability.)
• $20,307,784 — Accumulated Deficit (As of March 31, 2025, highlighting significant historical losses.)
• $68,489 — Cash (Decreased by 47.8% from $130,840 at December 31, 2024, signaling liquidity issues.)
• $476,705 — Sales (Decreased by 24.0% from $627,750 in prior year, showing revenue decline.)
• $872,797 — Selling, General and Administrative Expenses (Increased by 75.2% from $498,198, driving higher operating losses.)
• $523,880 — Loss from Operations (Widened from $144,429 in prior year, reflecting operational inefficiencies.)
• 58,930,204 — Common Shares Outstanding (As of August 18, 2025, indicating potential for further dilution.)
• $0.01 — Loss per Share (For the three months ended March 31, 2025, reflecting shareholder impact.)

Key Players & Entities

• US NUCLEAR CORP. (company) — registrant
• Electronic Control Concepts (company) — acquired subsidiary
• Overhoff Technology Corporation (company) — acquired subsidiary
• SEC (regulator) — filing oversight
• Delaware (company) — state of incorporation
• Optron Scientific Company (company) — wholly-owned subsidiary

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company reported a net loss of $560,232 for the three months ended March 31, 2025, and an accumulated deficit of $20,307,784. This raises substantial doubt about its ability to continue as a going concern.
• Deteriorating Liquidity [high — financial]: Cash position decreased by 47.8% to $68,489 from $130,840 at December 31, 2024. Total current assets fell by 7.2% to $1,921,511, while total current liabilities decreased by 11.9% to $2,374,928, indicating a tightening cash situation.
• Surging SG&A Expenses [high — operational]: Selling, general, and administrative expenses increased by 75.2% to $872,797 from $498,198 in the prior year period. This surge is a primary driver of the widened operational loss.
• Need for Additional Capital [high — financial]: The company plans to seek additional capital through private placement offerings of debt and equity securities to mitigate going concern issues. Success of these offerings is critical for future operations.
• Revenue Decline [medium — market]: Sales decreased by 24.0% to $476,705 from $627,750 in the prior year period. This revenue contraction exacerbates the company's financial challenges.
• Growing Accumulated Deficit [high — financial]: The accumulated deficit grew to $20,307,784 as of March 31, 2025, reflecting significant historical losses and a persistent inability to achieve profitability.

Industry Context

The nuclear industry, particularly in areas like radiation detection and measurement, is subject to stringent regulatory oversight and requires significant R&D investment. Companies in this sector often face long sales cycles and depend on government contracts or specialized industrial applications. Competition can be intense, with established players and emerging technologies vying for market share.

Regulatory Implications

As a company involved in nuclear technology, US Nuclear Corp. is subject to extensive regulations from bodies like the Nuclear Regulatory Commission (NRC) and potentially the Department of Energy. Compliance with safety, security, and environmental standards is paramount and can incur significant costs. Changes in regulatory frameworks or enforcement can materially impact operations and market access.

What Investors Should Do

1. Monitor the success of the company's planned private placement offerings, as this is critical for addressing going concern issues and funding future operations.
2. Closely scrutinize future SG&A expenses to determine if the recent surge is a temporary anomaly or a sustained trend impacting profitability.
3. Evaluate the company's ability to reverse the current revenue decline and improve operational efficiency to achieve profitability.
4. Assess the long-term viability of the company's business model given the persistent accumulated deficit and current liquidity challenges.

Key Dates

• 2025-03-31: End of First Quarter 2025 — Reporting period for the 10-Q, showing a significant increase in net loss and a decrease in cash.
• 2024-12-31: End of Fiscal Year 2024 — Baseline for comparison of cash position and current assets/liabilities.

Glossary

Accumulated Deficit

The total cumulative net losses of a company that have not been offset by net income or other gains. (Indicates the company's long-term history of unprofitability, reaching $20,307,784 as of March 31, 2025.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. (The company explicitly states 'substantial doubt about its ability to continue as a going concern' due to its financial performance.)

Selling, General and Administrative Expenses (SG&A)

Costs incurred by a company that are not directly related to the production or acquisition of goods, but are necessary for the overall operation of the business. (These expenses surged by 75.2% to $872,797, significantly widening the net loss.)

Loss from Operations

The difference between a company's revenues and its operating expenses, excluding interest and taxes. (Widened to $523,880 from $144,429, highlighting operational inefficiencies and the impact of rising SG&A.)

Private Placement

A sale of securities directly to a small group of institutional investors or accredited individuals, rather than through a public offering. (The company plans to seek additional capital through this method to address its going concern issues.)

Year-Over-Year Comparison

Compared to the prior year period, US Nuclear Corp. has experienced a significant deterioration in financial performance. Revenue declined by 24.0% to $476,705, while Selling, General, and Administrative expenses surged by 75.2% to $872,797. This combination led to a substantial increase in net loss, from $161,978 to $560,232, and a widening loss from operations. The company's cash position has also significantly decreased, raising concerns about its ability to continue as a going concern.

Filing Documents

• ea0251460-10q_usnuclear.htm (10-Q) — 648KB
• ea025146001ex3-4i_usnuclear.htm (EX-3.4I) — 13KB
• ea025146001ex31-1_usnuclear.htm (EX-31.1) — 9KB
• ea025146001ex31-2_usnuclear.htm (EX-31.2) — 9KB
• ea025146001ex32-1_usnuclear.htm (EX-32.1) — 4KB
• ea025146001ex32-2_usnuclear.htm (EX-32.2) — 4KB
• image_001.jpg (GRAPHIC) — 5KB
• 0001213900-25-079934.txt ( ) — 5675KB
• ucle-20250331.xsd (EX-101.SCH) — 52KB
• ucle-20250331_cal.xml (EX-101.CAL) — 36KB
• ucle-20250331_def.xml (EX-101.DEF) — 283KB
• ucle-20250331_lab.xml (EX-101.LAB) — 496KB
• ucle-20250331_pre.xml (EX-101.PRE) — 296KB
• ea0251460-10q_usnuclear_htm.xml (XML) — 566KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24 PART II Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosures 26 Item 5. Other Information 26 Item 6. Exhibits 26

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. US NUCLEAR CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS March 31, December 31, 2025 2024 (unaudited) (audited) ASSETS CURRENT ASSETS Cash $ 68,489 $ 130,840 Accounts receivable, net 60,985 351,398 Note receivable 41,916 41,916 Inventories 1,750,121 1,536,014 Prepaid expenses and other current assets - 10,000 TOTAL CURRENT ASSETS 1,921,511 2,070,168 Property and equipment, net 1,604 1,964 Investments 4,539 4539 Goodwill 570,176 570,176 TOTAL ASSETS $ 2,497,830 $ 2,646,847 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 252,645 $ 256,276 Accounts payable - related party - - Accrued liabilities 1,111,480 1,025,954 Accrued compensation - officers 13,000 13,000 Customer deposit 302,607 423,548 Notes payable 135,411 169,624 Convertible notes payable, net of debt discount 144,000 405,403 Note payable to shareholder 104,512 92512 Line of credit 311,273 311,273 TOTAL CURRENT LIABILITIES 2,374,928 2,697,590 LONG-TERM LIABILITIES Notes payable 805,422 805,422 TOTAL LONG-TERM LIABILITIES 805,422 805,422 COMMITMENTS & CONTINGENCIES - - TOTAL LIABILITIES 3,180,350 3,503,012 SHAREHOLDERS' EQUITY: Common stock, $ 0.0001 par value; 100,000,000 shares authorized, 58,930,204 and 52,712,778 shares issued and outstanding 5,893 5,271 Common shares to be issued ( 593,556 shares) 87,362 45,813 Preferred stock, Series A, $ 0.0001 par value, 10,000 shares authorized, 2,006 and 2,006 , issued and outstanding 2,006,000 2,006,000 Additional paid in capital 17,526,009 16,763,076 Accumulated deficit ( 20,307,784 ) ( 19,676,325 ) TOTAL SHAREHOLDERS' EQUITY ( 682,520 ) ( 856,165 ) TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 2,497,830 $ 2,646,847 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 US NUCLEAR CORP. AND SU

financial statements

financial statements The unaudited interim financial statements included herein, presented in accordance with United States generally accepted accounting principles and Commission ("SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosure is adequate to make the information presented not misleading. These statements reflect all adjustment, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. It is suggested that these interim financial statements be read in conjunction with the financial 10-K filed on June 25, 2025. The Company follows the same accounting policies in the preparation of interim reports. Results of operations for the interim period are not indicative of annual results. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company recorded a net loss of $ 560,232 for the three months ended March 31, 2025, and had an accumulated deficit of $ 20,307,784 as of March 31, 2025, which raises substantial doubt about its ability to continue as a going concern. The Company's ability to continue as a going concern is dependent upon its ability to generate profitable operations in the future and/or obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek addition

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 Cash and Cash Equivalents Cash and cash equivalents include cash on hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. There were no cash equivalents as of March 31, 2025, and December 31, 2024. Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company places its cash with high quality financial institutions and at times may exceed the FDIC insurance limit. The Company has not and does not anticipate incurring any losses related to this credit risk. Accounts Receivable The Company maintains reserves for potential credit losses for accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. Reserves are recorded based on the Company's historical collection history in addition to an analysis of future potential credit losses. Management considers the aging of accounts receivable, changes to customer credit ratings, as well as any industry-specific factors and economic growth trends that could impact credit loss estimates. Allowance for doubtful accounts as of March 31, 2025, and December 31, 2024 were $ 6,590 and $ 6,590 , respectively. Inventories Inventories are valued at the lower of cost (determined primarily by the average cost method) or net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. As of March 31, 2025, and December 31, 2024, the Company recorded $ 37,351 and $ 37,351 , respectively, in allowanc

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 Property and Equipment Property and Equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of equipment is provided using the straight-line method for substantially all assets with estimated lives as follows: Furniture and fixtures 5 years Leasehold improvement Lesser of lease life or economic life Equipment 5 years Computers and software 5 years Long-Lived Assets The Company applies the provisions of Accounting Standards Codification ("ASC") Topic 360, Property, Plant, and Equipment , which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at March 31, 2025, and December 31, 2024, the Company believes there was no impairment of its long-lived assets. Goodwill Goodwill represents the excess of the purchase price over the underlying net assets of businesses acquired. The entire goodwill balance in the accompanying financial statements resulted from the Company's acquisition of Overhoff Technology Corporation in 2006. The Company complies with ASC 350, Goodwill and Other Inde

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 Investments The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, the Company measures the equity security at fair value as of the date that the observable transaction occurred ("the measurement alternative") in accordance with ASC 321. The Company accounts for investments for which it owns 20 % or more, but less than 50 % on the equity method in accordance with ASC 323. Fair Value of Financial Instruments For certain of the Company's financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities, customer deposits, and line of credit, the carrying amounts approximate their fair values due to their short maturities. In addition, the Company has a note payable to a shareholder that the carrying amount also approximates fair value. Convertible Preferred Stock The Company has authorized 10,000 shares of Series A Convertible Preferred Stock, each share convertible into 10,000 shares of the Company's common stock. The preferred stock carries a dividend rate of 6 % per annum, payable quarterly within 90 days of the applicable quarter, and 1,200 shares of common stock for each share of Series A titled to each holder. At any time after January 31, 2026, the Company has the right, but is not obligated, to call and redeem any outstanding Series A Preferred for $ 1,000 per share or to convert each share of Series A Preferred into 10,000 common shares. The Series A Convertible Preferred mature on January 31, 2028, at which time the Company shall convert all Series A Preferred into 10,000 common shares per Preferred. The Company relied upon guidance and accounted for the Series A Convertible Preferred in accordance with ASC 480 and

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 These five elements, as applied to each of the Company's revenue categories, are summarized below: Product sales - revenue is recognized when the Company performs its obligations under the contracts it has with its customers to deliver products at an agreed upon price and it is generally when the control of the product has been transferred to the customer. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as customer deposits. Sales returns and allowances were $ 0 and $ 0 for the three months ended March 31, 2025, and 2024, respectively. The Company provides a one-year warranty on all sales. Warranty expense for the three months ended March 31, 2025, and 2024 was insignificant. The Company does not provide unconditional right of return, price protection or any other concessions to its customers. See Notes 11 and 12 for disclosures of revenue disaggregated by geographical area and product line. Customer Deposits Customer deposits represent cash paid to the Company by customers before the product has been completed and shipped and are considered fully refundable. Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes . ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share . Basic earnings per share ("EPS") is based on the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive convertible shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. For periods in which the Company has reported net loss, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, because dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Three Months Ended March 31, 2025 2024 Common Stock Common Stock Numerator: Net income (loss) $ ( 560,232 ) $ ( 161,978 ) Preferred stock dividends ( 71,227 ) - Net income (loss) attributable to common stockholders $ ( 631,459 ) $ ( 161,978 ) Denominator: Weighted-average shares used to compute net income (loss) per share attributable to common stockholders—basic 57,309,903 42,526,088 Effect of dilu

View Full Filing

View this 10-Q filing on SEC EDGAR